Alkermes Plc
ALKS28.520USD
+0.030+0.11%
Close 12/24, 16:00（ET）Quotes delayed by 15 min
4.71BMarket Cap
13.82P/E TTM
More Details of Alkermes Plc Company
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Alkermes Plc Info
Ticker SymbolALKS
Company nameAlkermes Plc
IPO dateJul 16, 1991
CEOPops (Richard F)
Number of employees1800
Security typeOrdinary Share
Fiscal year-endJul 16
AddressConnaught House
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD04 C5Y6
Phone35317728000
Websitehttps://www.alkermes.com/
Ticker SymbolALKS
IPO dateJul 16, 1991
CEOPops (Richard F)
Company Executives of Alkermes Plc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.74K
-5.74%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
+26.46%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
+12.23%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
10.71K
+131.91%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
205.37K
+0.55%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.74K
-5.74%
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
Other
21.09M
5.40%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
121.66M
31.14%
ARISTADA
101.30M
25.93%
LYBALVI
84.28M
21.57%
Royalty Revenue - VUMERITY
32.02M
8.20%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
30.32M
7.76%
Other
21.09M
5.40%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.33%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
6.09%
State Street Investment Management (US)
5.17%
Baker Bros. Advisors LP
4.90%
Other
58.54%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.33%
The Vanguard Group, Inc.
10.98%
T. Rowe Price Associates, Inc.
6.09%
State Street Investment Management (US)
5.17%
Baker Bros. Advisors LP
4.90%
Other
58.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
28.01%
Hedge Fund
17.63%
Pension Fund
2.30%
Research Firm
2.18%
Individual Investor
1.48%
Sovereign Wealth Fund
1.18%
Bank and Trust
0.44%
Private Equity
0.42%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
744
175.23M
117.54%
-23.12K
2025Q3
767
175.30M
122.16%
+2.11M
2025Q2
769
173.38M
125.62%
-4.15M
2025Q1
759
177.46M
124.05%
-27.05M
2024Q4
734
172.08M
130.58%
-12.03M
2024Q3
705
184.36M
134.23%
-884.11K
2024Q2
687
185.17M
126.42%
+3.87M
2024Q1
659
181.61M
124.10%
-28.36M
2023Q4
633
182.01M
111.83%
+12.84M
2023Q3
601
169.31M
104.05%
+9.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
23.73M
14.37%
-251.67K
-1.05%
Jun 30, 2025
The Vanguard Group, Inc.
18.45M
11.18%
+290.40K
+1.60%
Jun 30, 2025
T. Rowe Price Associates, Inc.
9.86M
5.97%
-1.76M
-15.13%
Jun 30, 2025
State Street Investment Management (US)
8.21M
4.97%
+185.59K
+2.31%
Jun 30, 2025
Baker Bros. Advisors LP
6.41M
3.88%
+1.93M
+42.99%
Jun 30, 2025
Renaissance Technologies LLC
5.81M
3.52%
+71.33K
+1.24%
Jun 30, 2025
American Century Investment Management, Inc.
3.66M
2.22%
+191.55K
+5.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.02M
2.44%
+83.86K
+2.13%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.10M
1.88%
+105.63K
+3.53%
Jun 30, 2025
JP Morgan Asset Management
3.95M
2.39%
-179.85K
-4.36%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
7.31%
iShares Neuroscience and Healthcare ETF
3.82%
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Invesco S&P SmallCap Health Care ETF
3.1%
ALPS Medical Breakthroughs ETF
2.07%
Knowledge Leaders Developed World ETF
1.69%
Langar Global HealthTech ETF
1.44%
State Street SPDR S&P Biotech ETF
1.35%
Abacus FCF International Leaders ETF
1.34%
Invesco S&P SmallCap Quality ETF
1.32%
View more
AdvisorShares Psychedelics ETF
Proportion7.31%
iShares Neuroscience and Healthcare ETF
Proportion3.82%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.3%
Invesco S&P SmallCap Health Care ETF
Proportion3.1%
ALPS Medical Breakthroughs ETF
Proportion2.07%
Knowledge Leaders Developed World ETF
Proportion1.69%
Langar Global HealthTech ETF
Proportion1.44%
State Street SPDR S&P Biotech ETF
Proportion1.35%
Abacus FCF International Leaders ETF
Proportion1.34%
Invesco S&P SmallCap Quality ETF
Proportion1.32%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alkermes Plc?
The top five shareholders of Alkermes Plc are:
BlackRock Institutional Trust Company, N.A. holds 23.73M shares, accounting for 14.37% of the total shares.
The Vanguard Group, Inc. holds 18.45M shares, accounting for 11.18% of the total shares.
T. Rowe Price Associates, Inc. holds 9.86M shares, accounting for 5.97% of the total shares.
State Street Investment Management (US) holds 8.21M shares, accounting for 4.97% of the total shares.
Baker Bros. Advisors LP holds 6.41M shares, accounting for 3.88% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 23.73M shares, accounting for 14.37% of the total shares.
The Vanguard Group, Inc. holds 18.45M shares, accounting for 11.18% of the total shares.
T. Rowe Price Associates, Inc. holds 9.86M shares, accounting for 5.97% of the total shares.
State Street Investment Management (US) holds 8.21M shares, accounting for 4.97% of the total shares.
Baker Bros. Advisors LP holds 6.41M shares, accounting for 3.88% of the total shares.
What are the top three shareholder types of Alkermes Plc?
The top three shareholder types of Alkermes Plc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
How many institutions hold shares of Alkermes Plc (ALKS)?
As of 2025Q4, 744 institutions hold shares of Alkermes Plc, with a combined market value of approximately 175.23M, accounting for 117.54% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.62%.
What is the biggest source of revenue for Alkermes Plc?
In FY2025Q2, the VIVITROL business generated the highest revenue for Alkermes Plc, amounting to 121.66M and accounting for 31.14% of total revenue.
